摘要:
The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine.
摘要:
The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine.
摘要:
A method for the quantitative characterization of substances with regard to their properties of binding to amyloid-β (Aβ) conformers, comprising the steps of: —fractionating a sample including various Aβ conformers; —immobilizing a biotinylated Aβ conformer of the desired fraction on the surface of a substrate having high affinity for biotin; and —deriving the binding behavior of an aggregate quality control probe to the desired Aβ conformer from the measurement signal by determining the kinetic and/or thermodynamic parameters. A device for carrying out the method.
摘要:
The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.
摘要:
The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.
摘要:
The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.
摘要:
A method for the quantitative characterization of amyloid and/or aggregated peptides and/or proteins in a sample, comprising:—providing a sample, wherein the sample includes an amyloid and/or aggregated peptide and/or protein having at least one aggregate size and shape;—adding an active ingredient to be analyzed to the sample solution;—separating the amyloid and/or aggregated peptides and/or proteins are from one another according to their aggregate size and shape;—optionally completely denaturing the amyloid and/or aggregated peptides and/or proteins of a particular fraction into monomer building blocks;—determining the change in concentration of the peptide and/or protein building blocks in at least one fraction by comparison against control values without the active ingredient.